Ann: Trading Halt, page-45

A two-day trading halt in anticipation of negative results would be a uncommon strategy, (but not out of the realm of possibility) as such news is typically released after market close without prior warning. Ideally, another strong performance from the NBI overnight could pave the way for a positive market response on Monday morning, allowing the market a full week to digest the news

I’m confident that the Phase 2 results of the XanaCIDD trial will be positive for several reasons. Firstly, the solid safety profile established in Phase 1 lays a robust foundation for success in subsequent phases. Furthermore, the well-characterized mechanism of action, which is directly aligned with the therapeutic target, significantly enhances the likelihood of demonstrating efficacy. Additionally, the trial’s design, featuring a meticulously selected patient population should to yield favourable outcomes.

A reduction exceeding 30% would be particularly encouraging, especially given the previously shared comments indicating that the trial is "trending in the right direction”, coupled with positive prior data readouts and the fact that Phase 3 trials are already planned, there is a strong likelihood that the results will be favourable.